Literature DB >> 18308563

Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.

Philip Jones1, Sergio Altamura, Raffaele De Francesco, Paola Gallinari, Armin Lahm, Petra Neddermann, Michael Rowley, Sergio Serafini, Christian Steinkühler.   

Abstract

It has been widely debated whether class IIa HDACs have catalytic deacetylase activity, and whether this plays any part in controlling gene expression. Herein, it has been demonstrated that class IIa HDACs isolated from mammalian cells are contaminated with other deacetylases, but can be prepared cleanly in Escherichia coli. These bacteria preparations have weak but measurable deacetylase activity. The low efficiency can be restored either by: mutation of an active site histidine to tyrosine, or by the use of a non-acetylated lysine substrate, allowing the development of assays to identify class IIa HDAC inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308563     DOI: 10.1016/j.bmcl.2008.02.025

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  41 in total

1.  Epigenetics in anoxia tolerance: a role for histone deacetylases.

Authors:  Anastasia Krivoruchko; Kenneth B Storey
Journal:  Mol Cell Biochem       Date:  2010-05-01       Impact factor: 3.396

2.  Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle.

Authors:  Douglas D Lemon; Brooke C Harrison; Todd R Horn; Matthew S Stratton; Bradley S Ferguson; Michael F Wempe; Timothy A McKinsey
Journal:  FEBS Lett       Date:  2015-03-25       Impact factor: 4.124

3.  Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA.

Authors:  Hsin-Hsien Yeh; Mei Tian; Rainer Hinz; Daniel Young; Alexander Shavrin; Uday Mukhapadhyay; Leo G Flores; Julius Balatoni; Suren Soghomonyan; Hwan J Jeong; Ashutosh Pal; Rajesh Uthamanthil; James N Jackson; Ryuichi Nishii; Hiroshi Mizuma; Hirotaka Onoe; Shinya Kagawa; Tatsuya Higashi; Nobuyoshi Fukumitsu; Mian Alauddin; William Tong; Karl Herholz; Juri G Gelovani
Journal:  Neuroimage       Date:  2012-09-17       Impact factor: 6.556

Review 4.  Selective class IIa HDAC inhibitors: myth or reality.

Authors:  Eros Di Giorgio; Enrico Gagliostro; Claudio Brancolini
Journal:  Cell Mol Life Sci       Date:  2014-09-05       Impact factor: 9.261

5.  Specific activity of class II histone deacetylases in human breast cancer cells.

Authors:  Vanessa Duong; Caroline Bret; Lucia Altucci; Antonello Mai; Céline Duraffourd; Julie Loubersac; Pierre-Olivier Harmand; Sandrine Bonnet; Sergio Valente; Thierry Maudelonde; Vincent Cavailles; Nathalie Boulle
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

6.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

7.  Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease.

Authors:  Mark Kilgore; Courtney A Miller; Daniel M Fass; Krista M Hennig; Stephen J Haggarty; J David Sweatt; Gavin Rumbaugh
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

8.  Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.

Authors:  Chunping Xu; Elisabetta Soragni; C James Chou; David Herman; Heather L Plasterer; James R Rusche; Joel M Gottesfeld
Journal:  Chem Biol       Date:  2009-09-25

9.  Chemical phylogenetics of histone deacetylases.

Authors:  James E Bradner; Nathan West; Melissa L Grachan; Edward F Greenberg; Stephen J Haggarty; Tandy Warnow; Ralph Mazitschek
Journal:  Nat Chem Biol       Date:  2010-02-07       Impact factor: 15.040

Review 10.  Manipulation of the host protein acetylation network by human immunodeficiency virus type 1.

Authors:  Mark Y Jeng; Ibraheem Ali; Melanie Ott
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-09-02       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.